Our Omnichannel Maturity tool is designed for biopharmaceutical, healthcare technology, and wellness companies that are driven to develop integrated and customer-centric omnichannel experiences.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh